Clinical Pearls Podcasts

MediCom Oncology Clinical Pearls Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting. For more tips and advice on best practices in patients, subscribe to our channel on iTunes.

What is the significance of minimal residual disease (MRD) as a surrogate marker in myeloma?

Shaji K. Kumar, MD

Clinical Pearls Podcasts published on April 7, 2021

How does adding a fourth drug to a myeloma treatment regimen affect the side effect burden?

Shaji K. Kumar, MD

Clinical Pearls Podcasts published on April 2, 2021

What is the rationale for utilizing quadruplet therapy for frontline treatment of myeloma?

Shaji K. Kumar, MD

Clinical Pearls Podcasts published on March 25, 2021

Targeting BCMA in Multiple Myeloma and the Approval of Belantamab Mafodotin

Sagar Lonial, MD, FACP

Clinical Pearls Podcasts published on October 30, 2020

How will ASTX727 be used in clinic?

Guillermo Garcia-Manero, MD

Clinical Pearls Podcasts published on September 14, 2020

Combination of oral cedazuridine and decitabine, known as ASTX727, in patients with MDS

Guillermo Garcia-Manero, MD

Clinical Pearls Podcasts published on September 9, 2020

Pracinostat with Azacitidine in the Treatment of Patients with MDS

Ehab Atallah, MD

Clinical Pearls Podcasts published on July 31, 2020

How to utilize and sequence new drugs in the treatment of AML

Eytan M. Stein, MD

Clinical Pearls Podcasts published on April 8, 2020

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory AML

Clinical Pearls Podcasts published on March 23, 2020

Q-TWIST Analysis of Quizartinib vs. Salvage Chemotherapy in Patients with R/R FLT3-ITD AML

Jorge E. Cortes, MD

Clinical Pearls Podcasts published on March 6, 2020

12 »End

Page 1 of 2
Results 1 - 10 of 20

Clinical Pearls Podcasts

MediCom Worldwide, Inc. Links